Precedence Research analyzes the new publication titled “Cancer Drugs Market (By Drug Class: Targeted Therapy, Chemotherapy, Hormonal Therapy, and Immunotherapy; By Indication: Lungs Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030”, As per the report, the cancer drugs market size was US$ 136.2 billion in 2020. It is projected to grow US$ 272 billion by 2030 at a CAGR of 7.2% in the forecast period.
Download the FREE Sample Report (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1415
Market Overview
A recent study by Precedence Research on the cancer drugs market offers a forecast for 2021 and 2030. The study analyzes crucial trends that are currently determining the growth of the cancer drugs market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of cancer drugs. The study also provides the dynamics that are responsible for influencing the future status of this market over the forecast period.
A detailed assessment of the cancer drugs market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the cancer drugs market along with their product portfolio enhances the reliability of this comprehensive research study.
Highlights of the Report:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market
Key Points
- Primary Research
- Secondary Research
- Market Size Estimation
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Technology Trends and Assessment
- Market Factor Analysis
- Porter’s Five Forces Analysis
- Bargaining Power Of Suppliers
- Bargaining Power Of Buyers
- Threat Of New Entrants
- Threat Of Substitutes
- Intensity Of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
Research Methodology
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, the structure of the market participants and industry's competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
Industry participants involved in this research study include:
- CEOs, VPs, market intelligence managers
- Procuring and national sales managers technical personnel, distributors and resellers
- Research analysts and key opinion leaders from various domains
Competition Landscape
In the final section of the report on the global cancer drugs market, a 'dashboard view' of the companies has been provided to compare the current market scenario and the contribution of companies to the global cancer drugs market. Moreover, the report is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to segments of the global market. Report audiences can gain segment-specific manufacturer insights to identify and evaluate key competitors based on an in-depth assessment of their capabilities and success in the cancer drugs marketplace.
Some of the prominent players in the global cancer drugs market include:
- Amgen
- Bayer Healthcare AG
- CELGENE CORPORATION
- GlaxoSmithKline
- ARIAD Pharmaceuticals, Inc.
- Eli Lilly and Company
- Novartis
- Hoffmann-La Roche Ltd.
- AstraZeneca
- BoehringerIngelheim GmbH
- Pfizer
- Teva Pharmaceuticals Industries
Market Segmentation
Segments of the global cancer drugs market have been analyzed in terms of their market share to understand an individual segment’s relative contribution to market growth. This detailed level of information is important for identifying key trends in the global cancer drugs market.
Market Segments as below:
By Drug Class
- Targeted Therapy
- Chemotherapy
- Hormonal Therapy
- Immunotherapy
By Indication
- Lungs Cancer
- Colorectal Cancer
- Breast Cancer
- Liver Cancer
- Bladder Cancer
- Head & Neck Cancer
- Prostate Cancer
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Drugs Market
5.1. COVID-19 Landscape: Cancer Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Drugs Market, By Drug Class
8.1. Cancer Drugs Market, by Drug Class Type, 2021-2030
8.1.1. Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Chemotherapy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hormonal Therapy
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Immunotherapy
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Drugs Market, By Indication
9.1. Cancer Drugs Market, by Indication, 2021-2030
9.1.1. Lungs Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Breast Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Liver Cancer
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Bladder Cancer
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Head & Neck Cancer
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Prostate Cancer
9.1.7.1. Market Revenue and Forecast (2019-2030)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.1.2. Market Revenue and Forecast, by Indication (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Indication (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Indication (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.2. Market Revenue and Forecast, by Indication (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Indication (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Indication (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Indication (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Indication (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.2. Market Revenue and Forecast, by Indication (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Indication (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Indication (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Indication (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Indication (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.2. Market Revenue and Forecast, by Indication (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Indication (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Indication (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Indication (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Indication (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.5.2. Market Revenue and Forecast, by Indication (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Indication (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Indication (2019-2030)
Chapter 11. Company Profiles
11.1. Amgen
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bayer Healthcare AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. CELGENE CORPORATION
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GlaxoSmithKline
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. ARIAD Pharmaceuticals, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Eli Lilly and Company
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Hoffmann-La Roche Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. AstraZeneca
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim GmbH
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Why Buy this Report?
The purpose of Precedence Research's cancer drugs market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1415
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments